Methotrexate 50 Mg 1 Vials

Methotrexate 50 Mg 1 Vials

Description:

Methotrexate 50 mg vial is a prescription antimetabolite, antifolate, immunosuppressant and antineoplastic medicine used in the treatment of various cancers and severe autoimmune diseases. It inhibits dihydrofolate reductase, reducing folic acid–dependent DNA, RNA and protein synthesis, which slows or stops the growth of rapidly dividing cells and modulates immune activity. This injectable formulation is intended for use by healthcare professionals only in hospital or clinical settings, following strict oncology and rheumatology treatment protocols.

Indications:

• Acute lymphoblastic leukemia (ALL) – as part of combination chemotherapy regimens.
• Choriocarcinoma and other gestational trophoblastic neoplasms (including hydatidiform mole).
• Burkitt's lymphoma and other non-Hodgkin lymphomas such as lymphosarcoma (as per protocol).
• Meningeal leukemia – for intrathecal or systemic therapy as indicated by specialist.
• Non-metastatic osteosarcoma – as part of multi-agent chemotherapy.
• Mycosis fungoides (cutaneous T-cell lymphoma) – in selected cases.
• Severe, treatment-resistant psoriasis that is not adequately controlled by other therapies.
• Moderate to severe active rheumatoid arthritis in adults when response to other disease-modifying antirheumatic drugs (DMARDs) is inadequate.
• Corticosteroid-dependent or severe asthma (off-label in selected cases under specialist supervision).
• Other autoimmune or inflammatory conditions as determined by a specialist (off-label, according to guidelines).

Active Ingredients / Key Components:

• Methotrexate – 50 mg per vial (concentration per ml not specified in the available information (For full ingredient information, please check the product leaflet or the manufacturer’s official website.)).
• Excipients: Specific inactive ingredients (such as buffering agents, preservatives, or diluents) are not provided in the available information (For full ingredient information, please check the product leaflet or the manufacturer’s official website.).

Dosage & Administration / How to Use:

• Methotrexate 50 mg vial is for parenteral use only (injection). Routes may include intravenous (iv), intramuscular (im), subcutaneous (sc), or intrathecal administration, depending on indication and protocol.
• Dosage is highly individualized based on the disease being treated, patient body surface area (bsa) or weight, organ function, and concomitant therapies. Typical regimens differ markedly between oncology and rheumatology indications.
• For cancer chemotherapy: Administer strictly according to established protocols (e.g., high-dose methotrexate regimens with mandatory leucovorin rescue and intensive hydration/alkalinization). Only experienced oncologists/hematologists should prescribe and supervise treatment.
• For autoimmune diseases (e.g., rheumatoid arthritis, psoriasis): Lower weekly doses are used. Methotrexate must be given once weekly, never as a daily dose, to avoid severe toxicity. Exact dose, route, and titration schedule must be determined by a specialist.
• Must be prepared and administered by trained healthcare professionals using aseptic technique in an appropriate clinical setting.
• Folic acid or folinic acid (leucovorin) supplementation is often required to reduce toxicity, as directed by the treating physician.
• Regular monitoring of complete blood count, liver function tests, renal function, and, when indicated, methotrexate serum levels is mandatory.
• Do not self-inject or adjust the dose without medical supervision. This product is not for self-medication.

Clinical Benefits:

• Provides effective antineoplastic activity against selected leukemias, lymphomas, osteosarcoma, and gestational trophoblastic disease by inhibiting DNA synthesis in rapidly dividing cells.
• Acts as a potent disease-modifying antirheumatic drug (DMARD), helping to reduce joint inflammation, pain, and structural damage in rheumatoid arthritis.
• Helps control severe, recalcitrant psoriasis by suppressing abnormal keratinocyte proliferation and modulating immune responses.
• Offers immunosuppressive effects beneficial in certain steroid-dependent or resistant inflammatory conditions, potentially reducing the need for long-term high-dose corticosteroids.

Warnings & Contraindications:

• Methotrexate is a high-risk medication with a narrow therapeutic index and should only be used under the supervision of experienced physicians familiar with its use and toxicity.
• Contraindicated in pregnancy (Category X) due to strong teratogenic and abortifacient effects. Women of childbearing potential and men must use effective contraception during treatment and for a recommended period after the last dose, as advised by their doctor.
• Contraindicated during breastfeeding, as methotrexate is excreted in breast milk and may cause serious adverse effects in the infant.
• Contraindicated in patients with severe hepatic impairment, significant renal impairment (unless dose-adjusted and closely monitored), severe bone marrow suppression, or pre-existing blood dyscrasias.
• Contraindicated in patients with known hypersensitivity to methotrexate or any component of the formulation.
• Use with extreme caution in patients with liver disease (including chronic alcohol use), kidney disease, active or chronic infections, peptic ulcer disease, or immunodeficiency.
• Avoid live vaccines during treatment and for an appropriate period after discontinuation unless specifically approved by a specialist.
• Concomitant use with other hepatotoxic, nephrotoxic, or myelosuppressive drugs, or with certain nonsteroidal anti-inflammatory drugs (nsaids), may increase toxicity and must be carefully managed.
• Regular monitoring of blood counts, liver and kidney function, and, where appropriate, chest imaging is essential to detect toxicity early.
• Consult your doctor before use if you have liver disease, kidney disease, lung disease, diabetes, active or recurrent infections, ulcers, or are taking any other medications, vitamins, or herbal supplements.
• Keep out of reach of children. Accidental ingestion or injection can be fatal.
• This information is not a substitute for professional medical advice. Always follow your doctor’s instructions and the official prescribing information.

Side Effects:

• Common side effects: nausea, vomiting, loss of appetite, abdominal discomfort, mouth sores (stomatitis), fatigue, headache, mild hair thinning, and elevated liver enzymes.
• Hematologic effects: bone marrow suppression leading to anemia, leukopenia, neutropenia, and thrombocytopenia, which may increase the risk of infections, bleeding, and fatigue.
• Gastrointestinal effects: mucositis, diarrhea, gastrointestinal ulceration, and, rarely, intestinal perforation.
• Hepatic effects: hepatotoxicity, including fibrosis and cirrhosis, especially with long-term use or in patients with pre-existing liver disease or alcohol use.
• Renal effects: nephrotoxicity, particularly with high doses or inadequate hydration.
• Pulmonary effects: acute or chronic interstitial pneumonitis, presenting with dry cough, shortness of breath, and fever; may be serious and requires immediate medical evaluation.
• Dermatologic effects: rash, photosensitivity, pruritus, and, rarely, severe skin reactions.
• Serious reactions: severe bone marrow suppression, severe infections, liver failure, kidney failure, pulmonary toxicity, and severe skin or allergic reactions. Seek urgent medical attention if you experience difficulty breathing, chest pain, severe or persistent fever, unusual bruising or bleeding, yellowing of the skin or eyes, or severe abdominal pain.

Storage Instructions:

Store in a cool, dry place away from direct sunlight, at the temperature specified on the package insert (typically below 25°c unless otherwise stated). Keep the vial in its original packaging until use. Do not freeze unless the product information specifically allows it. Keep container tightly closed and out of reach of children. Do not use after the expiry date printed on the pack. Discard any unused solution according to local cytotoxic waste disposal regulations.

Specifications:

• Product type: Prescription antimetabolite, antifolate, immunosuppressant, antineoplastic medicine.
• Form: Powder/solution for injection in a single-use vial (50 mg methotrexate per vial; exact volume or reconstitution details not specified in the available information (For full ingredient information, please check the product leaflet or the manufacturer’s official website.)).
• Pack size: 1 vial per pack.
• Route of administration: Parenteral (iv, im, sc, or intrathecal) as directed by a specialist.
• Intended user: Adults and children as indicated, under specialist supervision only.

Disclaimer:
All pharmacy products are intended for general use only and do not replace professional medical advice, diagnosis, or treatment. Always consult a healthcare provider before use. Results may vary, and no specific outcomes are guaranteed. Products are not intended to diagnose, treat, cure, or prevent any disease unless stated. Follow label instructions carefully, as misuse may cause adverse effects. Compliance with local laws is the customer’s responsibility.